CN106420809B - A kind of ophthalmologic operation perfusion liquid - Google Patents
A kind of ophthalmologic operation perfusion liquid Download PDFInfo
- Publication number
- CN106420809B CN106420809B CN201610787864.1A CN201610787864A CN106420809B CN 106420809 B CN106420809 B CN 106420809B CN 201610787864 A CN201610787864 A CN 201610787864A CN 106420809 B CN106420809 B CN 106420809B
- Authority
- CN
- China
- Prior art keywords
- extract
- ophthalmologic operation
- low
- perfusion liquid
- mulberries
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 50
- 230000010412 perfusion Effects 0.000 title claims abstract description 36
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims abstract description 24
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 24
- 239000011780 sodium chloride Substances 0.000 claims abstract description 13
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 12
- 239000001110 calcium chloride Substances 0.000 claims abstract description 12
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 claims abstract description 12
- 229910001629 magnesium chloride Inorganic materials 0.000 claims abstract description 12
- 239000001103 potassium chloride Substances 0.000 claims abstract description 12
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 12
- 238000011084 recovery Methods 0.000 claims abstract description 9
- 239000000284 extract Substances 0.000 claims description 55
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 42
- 239000000843 powder Substances 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 241000195474 Sargassum Species 0.000 claims description 24
- 235000008708 Morus alba Nutrition 0.000 claims description 23
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 23
- 235000011613 Pinus brutia Nutrition 0.000 claims description 23
- 241000018646 Pinus brutia Species 0.000 claims description 23
- 241000218231 Moraceae Species 0.000 claims description 22
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 18
- 235000003365 Ilex pubescens Nutrition 0.000 claims description 17
- 241001100932 Ilex pubescens Species 0.000 claims description 17
- 239000000706 filtrate Substances 0.000 claims description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000000227 grinding Methods 0.000 claims description 11
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 9
- 229930003268 Vitamin C Natural products 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 235000019154 vitamin C Nutrition 0.000 claims description 9
- 239000011718 vitamin C Substances 0.000 claims description 9
- 235000002961 Aloe barbadensis Nutrition 0.000 claims description 8
- 239000012535 impurity Substances 0.000 claims description 8
- 239000008215 water for injection Substances 0.000 claims description 8
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 7
- 239000001509 sodium citrate Substances 0.000 claims description 7
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 7
- 239000011576 zinc lactate Substances 0.000 claims description 7
- 235000000193 zinc lactate Nutrition 0.000 claims description 7
- 229940050168 zinc lactate Drugs 0.000 claims description 7
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 235000011399 aloe vera Nutrition 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 150000004676 glycans Chemical class 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 6
- 239000005017 polysaccharide Substances 0.000 claims description 6
- 235000017281 sodium acetate Nutrition 0.000 claims description 6
- 229940087562 sodium acetate trihydrate Drugs 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 244000186892 Aloe vera Species 0.000 claims 1
- 238000003810 ethyl acetate extraction Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 210000001508 eye Anatomy 0.000 abstract description 15
- 230000002980 postoperative effect Effects 0.000 abstract description 11
- 208000002177 Cataract Diseases 0.000 abstract description 8
- 230000009471 action Effects 0.000 abstract description 8
- 239000003855 balanced salt solution Substances 0.000 abstract description 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 11
- 210000000695 crystalline len Anatomy 0.000 description 8
- 244000144927 Aloe barbadensis Species 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 108010024636 Glutathione Proteins 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 230000004438 eyesight Effects 0.000 description 5
- 229960003180 glutathione Drugs 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 239000013010 irrigating solution Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 229940082569 selenite Drugs 0.000 description 3
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229940006091 aloe polysaccharide Drugs 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 210000001742 aqueous humor Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 241000165940 Houjia Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 206010024214 Lenticular opacities Diseases 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 208000034698 Vitreous haemorrhage Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- BDKZHNJTLHOSDW-UHFFFAOYSA-N [Na].CC(O)=O Chemical compound [Na].CC(O)=O BDKZHNJTLHOSDW-UHFFFAOYSA-N 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 210000000399 corneal endothelial cell Anatomy 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000006392 deoxygenation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical class [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- -1 hydrogen salt Chemical class 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of ophthalmologic operation perfusion liquid, by mass percentage, following component is included in the ophthalmologic operation perfusion liquid:Sodium chloride 0.64%, potassium chloride 0.075%, CaCl2·2H2O 0.048%, MgCl2·6H2O 0.03%.The present invention has preferably booster action to postoperative recovery, can effectively prevent cataract in vitretomized eyes in addition to the effect with general balanced salt solution.
Description
Technical field
The present invention relates to a kind of ophthalmologic operation assistant product, more particularly to a kind of ophthalmologic operation perfusion liquid.
Background technology
With the development of modern micro-surgical instruments, ophthalmologic operation generally uses microinstrument, intraocular surgery technology day
Become to improving and ripe.Generally carry out in situation of all-level hospitals cataract extraction, vitrectomy is also begun to big-and-middle
Type hospital progressively carries out, and its quantity increases year by year, has saved many blindness or the eyes close to blindness.Vitrectomy,
It is one of ophthalmology routine operation, the treatment for a variety of eye diseases such as detachment of retina, vitreous hemorrhage.In surgical procedure
In, for balance intraocular pressure, the use of intraocular irrigating solution is essential.Conventional intraocular perfusion liquid is ophthalmology balanced salt solution, and this is molten
Liquid during preparation and use with the saturation of the air, contain higher partial pressure of oxygen(21.2kPa), in surgical procedure, with glass
The removal of glass body tissue, it is eliminated for the iris action of retinal vessel oxygen disperse, while using partial pressure containing higher oxygen in art
Intraocular irrigating solution so that crystalline lens is exposed in high keto sectional pressure environment, accelerate lenticular oxidative damage, induce postoperative white
The generation of cataract or glaucoma.
In recent years, with the more and more extensive Clinical practice of intraocular irrigating solution, its security is also more and more weighed
Depending on.Research shows, chemical composition, osmotic pressure, the buffer capacity of ion and temperature of the perfusion liquid used in intraocular surgery etc.
Material impact can be produced to the 26S Proteasome Structure and Function of the eye inner tissues such as post-operative cornea, crystalline lens, retina.Conventional ophthalmologic operation
Perfusion liquid is simple balanced salt solution, little to postoperative recovery booster action.Therefore, correct selection one kind is more conformed to
The perfusion liquid of intraocular normal physiological context, it will effectively reduce postoperative complications.
The content of the invention
It is an object of the invention to provide a kind of ophthalmologic operation perfusion liquid, except the effect with general balanced salt solution
Outside, there is preferably booster action to postoperative recovery, can effectively prevent cataract in vitretomized eyes.
The technical solution adopted for the present invention to solve the technical problems is:
A kind of ophthalmologic operation perfusion liquid, by mass percentage, includes following component in the ophthalmologic operation perfusion liquid:Chlorine
Change sodium 0.64%, potassium chloride 0.075%, CaCl2·2H2O 0.048%, MgCl2 ·6H2O 0.03%。
Preferably, by mass percentage, following component is also included in the ophthalmologic operation perfusion liquid:Three hydration acetic acid
Sodium 0.39%, sodium citrate 0.17%.
Preferably, by mass percentage, following component is also included in the ophthalmologic operation perfusion liquid:Disodium hydrogen phosphate
0.042%, sodium acid carbonate 0.21%, glucose 0.092%, oxidized form of glutathione 0.018%.Contain oxidized form of glutathione in formula
Contribute to Post operation to provide the apparent cornea visual field, containing oxidized form of glutathione, disodium hydrogen phosphate, bicarbonate component, make
It is compatible with endothelium more preferably, and glucose provides nutrition.The main buffer substance of disodium hydrogen phosphate, is also the main component of aqueous humor.
The perfusion liquid of potassium-containing hydrogen salt does not change corneal thickness, HCO3 -Active transport contributes to the performance of endothelial cell pumping function,
It can also maintain, extend human corneal endothelial cells current potential, contribute to the performance of retinal function.Glucose ocular tissue passes through grape
Glycometabolism produces energy, maintains the transparent and retina normal function of cornea and crystal.Glutathione is aqueous humor and crystal
Natural constituent, plays the role of to resisting oxidation free radical, can effectively remove the toxic work produced in ophthalmic surgical procedures
Free radical, can prevent the oxidative damage of the mercapto groups in albumen.Oxidized form of glutathione is through retina, choroid and angle
Reduced glutathione can be converted into quickly after the intake of film endothelial cell.
Preferably, by mass percentage, following component is also included in the ophthalmologic operation perfusion liquid:Zinc lactate
0.015%, aloe barbadensis Miller polysaccharide 0.02%, VB5 0.01%, Ilex pubescens extract 0.02%.
Add zinc lactate in the present invention to be mainly used in providing zinc ion, for preventing the surface of a wound from expanding, vitamin B5 is used to promote
Enter wound healing.Aloe barbadensis Miller polysaccharide is used for ophthalmologic operation perfusion liquid by the present invention first, and it has preferable bacteria resistance function,
Infection is prevented, the healing of wound can be effectively facilitated, have repairing effect well to the wound of ophthalmologic operation.While aloe barbadensis Miller
Polysaccharide has very strong antiallergic effect, and other compositions can be prevented to the stimulation of eye.Ilex pubescens extract can be antiviral
Infection, clearing liver cholagogic improves the blood circulation of part tissue of eye, and postoperative eye vision restoration and wound are recovered to have preferably to aid in
Effect.
Preferably, the preparation method of the Ilex pubescens extract is as follows:Ilex pubescens is freeze-dried, it is then super in low temperature
Low-temperature grinding to 300-500 mesh obtains ilex pubescens low temperature powder at 0-4 DEG C in atomizer, by ilex pubescens low temperature powder and mass concentration
90% ethanol solution is according to 1g:10mL solid-liquid ratio is well mixed, and ultrasonic power is ultrasonic extraction 15min, Ran Houjia under 450w
Heat extracts 3-5h to 45 DEG C, and filtering and impurity removing adds the activated carbon for accounting for filtrate weight 1-3% into filtrate, stirs 1-2 hours and takes off
Color, crosses and filters out the filter vacuum of activated carbon and be concentrated under reduced pressure recovery ethanol, obtain Ilex pubescens extract.
Preferably, by mass percentage, following component is also included in the ophthalmologic operation perfusion liquid:Mulberries extract
0.035%, fresh extract from pine needles 0.03%, vitamin C 0.01%, sargassum fusifome extract 0.018%.Mulberries extract nutrition is rich
Richness, liver-kidney tonifying, improving eyesight recovers have preferably booster action to postoperative eye vision restoration and wound.Fresh extract from pine needles battalion
Support abundant, rich in various trace elements and amino acid, calm the nerves, improving eyesight, improve the function of capillary, improve immunity, make group
Rejuvenation is knitted, having preferably booster action is recovered to postoperative eye vision restoration and wound.Sargassum fusifome extraction is with the addition of in raw material
Thing, its composition is mainly brown algae polyphenols, with very strong anti-oxidation function, also with antitumor activity, antiviral activity, deodorization
Activity etc..Vitamin C can reduce anaphylactoid generation, with very strong anti-oxidation function, suppress enzymatic browning, and protection is easy
Oxide, deoxygenation and free radical.The present invention is used cooperatively using sargassum fusifome extract with vitamin C, is had in terms of total antioxidation
There is good cooperative effect, improve fungistatic effect, promote wound healing, prevent the generation of postoperative cataract.
Preferably, the preparation method of the mulberries extract is:Mulberries are freeze-dried, it is then broken in low-temperature submicron powder
Low-temperature grinding to 100-200 mesh obtains mulberries low temperature powder at 0-4 DEG C in machine, by mulberries low temperature powder and deionized water according to 1g:15mL
Solid-liquid ratio be well mixed, be then heated to refluxing extraction 1-3 times, filtering and impurity removing, filter vacuum is concentrated under reduced pressure into original volume
20%, the filtrate weight 1-3% accounted for after concentration activated carbon is added into the filtrate after concentration, stirs 1-2 hours and decolourizes, cross and filter out
Activated carbon, obtains mulberries extract.
Preferably, the preparation method of the fresh extract from pine needles is as follows:Fresh pine needle is freeze-dried, it is then super in low temperature
Low-temperature grinding to 200-400 mesh obtains fresh pine needle low temperature powder at 0-4 DEG C in atomizer, by fresh pine needle low temperature powder and mass concentration
90% ethanol solution is according to 1g:10mL solid-liquid ratio is well mixed, and is then heated to 50 DEG C, extracts 3-5h, filtering and impurity removing, to
Added in filtrate and account for filtrate weight 1-3% activated carbon, stirred 1-2 hour and decolourize, cross filter out activated carbon filter vacuum depressurize it is dense
Retract and receive ethanol, obtain fresh extract from pine needles.
Preferably, the preparation method of the sargassum fusifome extract is as follows:Sargassum fusifome is freeze-dried, it is then super in low temperature
Low-temperature grinding to 200-400 mesh obtains sargassum fusifome low temperature powder at 0-4 DEG C in atomizer, and sargassum fusifome low temperature powder is pressed with 95% ethanol
According to 1g:10mL solid-liquid ratio mixing, is heated to extracting 1-2h at 55 DEG C, filters, filter vacuum is concentrated under reduced pressure into the 20% of original volume
Concentrate is obtained, the activated carbon for accounting for dope weight 1-3% is added into concentrate, stirs 1-2 hours and decolourizes, cross and filter out activated carbon;Most
Concentrate chloroform 3 times, is then extracted with ethyl acetate 3 times afterwards, and evaporated under reduced pressure removes ethyl acetate and obtains sargassum fusifome extraction
Thing.
The beneficial effects of the invention are as follows:In addition to the effect with general balanced salt solution, have preferably to postoperative recovery
Ground booster action, can effectively prevent cataract in vitretomized eyes.
Embodiment
Below by specific embodiment, technical scheme is described in further detail.
In the present invention, if not refering in particular to, raw material and equipment used etc. is commercially available or commonly used in the art.
Method in following embodiments, is the conventional method of this area unless otherwise instructed.
Embodiment 1:
A kind of ophthalmologic operation perfusion liquid, component is as follows:Sodium chloride 0.64%, potassium chloride 0.075%, CaCl2·2H2O
0.048%, MgCl2 ·6H2O 0.03%, sodium acetate trihydrate 0.39%, sodium citrate 0.17%, water for injection surplus.
Embodiment 2:
A kind of ophthalmologic operation perfusion liquid, component is as follows:Sodium chloride 0.64%, potassium chloride 0.075%, CaCl2·2H2O
0.048%, MgCl2 ·6H2O 0.03%, disodium hydrogen phosphate 0.042%, sodium acid carbonate 0.21%, glucose 0.092%, oxidized form paddy
The sweet peptide 0.018% of Guang, water for injection surplus, pH7.4.
Embodiment 3:
A kind of ophthalmologic operation perfusion liquid, component is as follows:Sodium chloride 0.64%, potassium chloride 0.075%, CaCl2·2H2O
0.048%, MgCl2 ·6H2O 0.03%, sodium acetate trihydrate 0.39%, sodium citrate 0.17%, zinc lactate 0.015%, Curacao
Aloe polysaccharide 0.02%, VB5 0.01%, Ilex pubescens extract 0.02%, water for injection surplus.
Embodiment 4:
A kind of ophthalmologic operation perfusion liquid, component is as follows:Sodium chloride 0.64%, potassium chloride 0.075%, CaCl2·2H2O
0.048%, MgCl2 ·6H2O 0.03%, disodium hydrogen phosphate 0.042%, sodium acid carbonate 0.21%, glucose 0.092%, oxidized form paddy
The sweet peptide 0.018% of Guang, zinc lactate 0.015%, aloe barbadensis Miller polysaccharide 0.02%, VB5 0.01%, Ilex pubescens extract 0.02%, note
Penetrate and use water surplus.
Embodiment 5:
A kind of ophthalmologic operation perfusion liquid, component is as follows:Sodium chloride 0.64%, potassium chloride 0.075%, CaCl2·2H2O
0.048%, MgCl2 ·6H2O 0.03%, sodium acetate trihydrate 0.39%, sodium citrate 0.17%, mulberries extract 0.035% is fresh
Extract from pine needles 0.03%, vitamin C 0.01%, sargassum fusifome extract 0.018%, water for injection surplus.
Embodiment 6:
A kind of ophthalmologic operation perfusion liquid, component is as follows:Sodium chloride 0.64%, potassium chloride 0.075%, CaCl2·2H2O
0.048%, MgCl2 ·6H2O 0.03%, sodium acetate trihydrate 0.39%, sodium citrate 0.17%, zinc lactate 0.015%, Curacao
Aloe polysaccharide 0.02%, VB5 0.01%, Ilex pubescens extract 0.02%, mulberries extract 0.035%, fresh extract from pine needles 0.03%,
Vitamin C 0.01%, sargassum fusifome extract 0.018%, water for injection surplus.
Embodiment 7:
A kind of ophthalmologic operation perfusion liquid, component is as follows:Sodium chloride 0.64%, potassium chloride 0.075%, CaCl2·2H2O
0.048%, MgCl2 ·6H2O 0.03%, disodium hydrogen phosphate 0.042%, sodium acid carbonate 0.21%, glucose 0.092%, oxidized form paddy
The sweet peptide 0.018% of Guang, mulberries extract 0.035%, fresh extract from pine needles 0.03%, vitamin C 0.01%, sargassum fusifome extract
0.018%, water for injection surplus.
Embodiment 8:
A kind of ophthalmologic operation perfusion liquid, component is as follows:Sodium chloride 0.64%, potassium chloride 0.075%, CaCl2·2H2O
0.048%, MgCl2 ·6H2O 0.03%, disodium hydrogen phosphate 0.042%, sodium acid carbonate 0.21%, glucose 0.092%, oxidized form paddy
The sweet peptide 0.018% of Guang, zinc lactate 0.015%, aloe barbadensis Miller polysaccharide 0.02%, VB5 0.01%, Ilex pubescens extract 0.02%, mulberry
Shen extracts 0.035%, fresh extract from pine needles 0.03%, vitamin C 0.01%, sargassum fusifome extract 0.018%, more than water for injection
Amount.
The preparation method of the Ilex pubescens extract is as follows:Ilex pubescens is freeze-dried, then in the broken machine of low-temperature submicron powder
Low-temperature grinding to 300-500 mesh obtains ilex pubescens low temperature powder at middle 0-4 DEG C, by ilex pubescens low temperature powder and the ethanol of mass concentration 90%
Solution is according to 1g:10mL solid-liquid ratio is well mixed, and ultrasonic power is ultrasonic extraction 15min under 450w, is then heated to 45 DEG C,
3-5h is extracted, filtering and impurity removing adds the activated carbon for accounting for filtrate weight 1-3% into filtrate, stirs 1-2 hours and decolourizes, crosses and filter out work
The filter vacuum of property charcoal is concentrated under reduced pressure recovery ethanol, obtains Ilex pubescens extract.
The preparation method of the mulberries extract is:Mulberries are freeze-dried, then 0-4 DEG C in the broken machine of low-temperature submicron powder
Lower low-temperature grinding to 100-200 mesh obtains mulberries low temperature powder, by mulberries low temperature powder and deionized water according to 1g:15mL solid-liquid ratio
It is well mixed, refluxing extraction is then heated to 1-3 times, filtering and impurity removing, filter vacuum is concentrated under reduced pressure into the 20% of original volume, to dense
The filtrate weight 1-3% accounted for after concentration activated carbon is added in filtrate after contracting, stirs 1-2 hours and decolourizes, cross and filter out activated carbon,
Obtain mulberries extract.
The preparation method of the fresh extract from pine needles is as follows:Fresh pine needle is freeze-dried, then in the broken machine of low-temperature submicron powder
Low-temperature grinding to 200-400 mesh obtains fresh pine needle low temperature powder at middle 0-4 DEG C, by fresh pine needle low temperature powder and the ethanol of mass concentration 90%
Solution is according to 1g:10mL solid-liquid ratio is well mixed, and is then heated to 50 DEG C, extracts 3-5h, and filtering and impurity removing is added into filtrate
Account for filtrate weight 1-3% activated carbon, stir 1-2 hour and decolourize, the filter vacuum that mistake filters out activated carbon is concentrated under reduced pressure recovery second
Alcohol, obtains fresh extract from pine needles.
The preparation method of the sargassum fusifome extract is as follows:Sargassum fusifome is freeze-dried, then in the broken machine of low-temperature submicron powder
Low-temperature grinding to 200-400 mesh obtains sargassum fusifome low temperature powder at middle 0-4 DEG C, by sargassum fusifome low temperature powder and 95% ethanol according to 1g:
10mL solid-liquid ratio mixing, is heated to extracting 1-2h at 55 DEG C, filters, and filter vacuum is concentrated under reduced pressure into the 20% of original volume and obtains dense
Contracting liquid, the activated carbon for accounting for dope weight 1-3% is added into concentrate, is stirred 1-2 hours and is decolourized, crosses and filter out activated carbon;It is last dense
Contracting liquid chloroform 3 times, is then extracted with ethyl acetate 3 times, and evaporated under reduced pressure removes ethyl acetate and obtains sargassum fusifome extract.
The ophthalmologic operation perfusion liquid of the present invention is mainly used in the operated eye for needing to be irrigated.In ophthalmologic operation, make
For the perfusion liquid outside intraocular or eye, most long infusion time must not exceed 60 minutes.After patient's use after 50 operated eyes,
After-operation response can be reduced, the morphosis and physiological function of basic holding ocular tissue, effect are substantially better than physiological saline, and clinic should
With working well, there is preferably booster action to postoperative recovery, can effectively prevent cataract in vitretomized eyes, nothing
Allergic reaction occurs.
Animal experiment:
Experimental subjects:Healthy 15 age of cleaning grade SD rat children mouses 90, body weight 25g or so, male and female and half.
Method:90 SD rats are randomly divided into Normal group, model control group and treatment group of the present invention, every group 30.
The preparation method of selenite induced catatract rat model is:2mmol/L sodium selenites are subcutaneously injected in 15 age in days SD rat children mouses nape parts
Physiological saline(20μmol/kg), the next day 1 time, continuous 5 days.Intraperitoneal injection of saline during Normal group modeling;Model comparison
Group is while selenite induced catatract model is induced, daily intraperitoneal injection of saline(5ml/kg), continuous 5 days;Present invention treatment
Group is while selenite induced catatract is induced, daily intraperitoneal injection perfusion liquid of the present invention(5ml/kg), continuous 5 days.
As a result:
Len's opacity is observed:1st after modeling is successful, 3,5,7 days observation lenticular muddinesses of each group animal
Degree.Carry out seeing under eyes mydriasis, slit-lamp microscope using compound tropicamide eye drops in each time point each group rat
Examine phacoscotasmus situation.Rats in normal control group crystalline lens in whole experiment process remains transparent, model control group
Crystalline lens is completely muddy, and the crystalline lens for the treatment of group 30% of the present invention is completely muddy, lesser extent.Compared with model control group, this hair
The generation of bright treatment group's phacoscotasmus is relative to be delayed, and turbidity is significantly lower than model control group.
The 7th day after success modeling, cervical dislocation puts to death each group rat, extracts eyeball, after being rinsed with physiological saline,
Eyeball is splitted from the way of escape under microscope, wall of eyeball and vitreum is removed, crystalline lens is taken out, PBS, ice-water bath condition is added after weighing
Lower homogenate, prepares 1000r/min centrifugation 10min under the conditions of tissue homogenate, 4 DEG C, goes supernatant biochemical assay to use each examination
SOD, CAT activity in agent box detection crystalline lens.
Treatment group SOD activity of the present invention is in 19.12U/mg or so, and CAT activity is in 6.32 U/mg or so;Normal group
SOD activity is in 21.36U/mg or so, and CAT activity is in 7.14 U/mg or so.Model control group SOD activity is left in 7.43U/mg
The right side, CAT activity is in 2.46 U/mg or so.Each numerical value for the treatment of group SOD, CAT activity of the present invention does not have compared with Normal group
Notable difference, model control group each numerical value of SOD, CAT activity compared with Normal group is significantly reduced;With model control group phase
Than SOD, CAT activity substantially increase in treatment group's crystalline lens of the present invention.
Embodiment described above is a kind of preferably scheme of the present invention, not makees any formal to the present invention
Limitation, also has other variants and remodeling on the premise of without departing from the technical scheme described in claim.
Claims (5)
1. a kind of ophthalmologic operation perfusion liquid, it is characterised in that by mass percentage, the component of the ophthalmologic operation perfusion liquid is such as
Under:Sodium chloride 0.64%, potassium chloride 0.075%, CaCl2·2H2O 0.048%, MgCl2 ·6H2O 0.03%, sodium acetate trihydrate
0.39%, sodium citrate 0.17%, mulberries extract 0.035%, fresh extract from pine needles 0.03%, vitamin C 0.01%, sargassum fusifome is carried
Take thing 0.018%, water for injection surplus.
2. a kind of ophthalmologic operation perfusion liquid, it is characterised in that by mass percentage, the component of the ophthalmologic operation perfusion liquid is such as
Under:Sodium chloride 0.64%, potassium chloride 0.075%, CaCl2·2H2O 0.048%, MgCl2 ·6H2O 0.03%, sodium acetate trihydrate
0.39%, sodium citrate 0.17%, zinc lactate 0.015%, aloe barbadensis Miller polysaccharide 0.02%, VB5 0.01%, Ilex pubescens extract
0.02%, mulberries extract 0.035%, fresh extract from pine needles 0.03%, vitamin C 0.01%, sargassum fusifome extract 0.018%, note
Penetrate and use water surplus.
3. a kind of ophthalmologic operation perfusion liquid according to claim 2, it is characterised in that the preparation side of the mulberries extract
Method is:Mulberries are freeze-dried, then in the broken machine of low-temperature submicron powder at 0-4 DEG C low-temperature grinding to 100-200 mesh to obtain mulberries low
Wen Fen, by mulberries low temperature powder and deionized water according to 1g:15mL solid-liquid ratio is well mixed, and is then heated to refluxing extraction 1-3
Secondary, filtering and impurity removing, filter vacuum is concentrated under reduced pressure into the 20% of original volume, and the filtrate accounted for after concentration is added into the filtrate after concentration
Weight 1-3% activated carbon, stirs 1-2 hours and decolourizes, cross and filter out activated carbon, obtain mulberries extract.
4. a kind of ophthalmologic operation perfusion liquid according to claim 2, it is characterised in that the preparation of the fresh extract from pine needles
Method is as follows:Fresh pine needle is freeze-dried, then low-temperature grinding to 200-400 mesh is obtained at 0-4 DEG C in the broken machine of low-temperature submicron powder
Fresh pine needle low temperature powder, by fresh pine needle low temperature powder and the ethanol solution of mass concentration 90% according to 1g:10mL solid-liquid ratio mixing is equal
It is even, 50 DEG C are then heated to, 3-5h is extracted, filtering and impurity removing adds the activated carbon for accounting for filtrate weight 1-3% into filtrate, stirs 1-
Decolourize within 2 hours, cross and filter out the filter vacuum of activated carbon and be concentrated under reduced pressure recovery ethanol, obtain fresh extract from pine needles.
5. a kind of ophthalmologic operation perfusion liquid according to claim 2, it is characterised in that the preparation of the sargassum fusifome extract
Method is as follows:Sargassum fusifome is freeze-dried, then low-temperature grinding to 200-400 mesh is obtained at 0-4 DEG C in the broken machine of low-temperature submicron powder
Sargassum fusifome low temperature powder, by sargassum fusifome low temperature powder and 95% ethanol according to 1g:10mL solid-liquid ratio mixing, is heated to extracting at 55 DEG C
1-2h, filtering, filter vacuum be concentrated under reduced pressure into original volume 20% concentrate, into concentrate add account for dope weight 1-3%
Activated carbon, stir 1-2 hour decolourize, mistake filter out activated carbon;Last concentrate chloroform 3 times, then uses ethyl acetate
Extraction 3 times, evaporated under reduced pressure removes ethyl acetate and obtains sargassum fusifome extract.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610787864.1A CN106420809B (en) | 2016-08-31 | 2016-08-31 | A kind of ophthalmologic operation perfusion liquid |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610787864.1A CN106420809B (en) | 2016-08-31 | 2016-08-31 | A kind of ophthalmologic operation perfusion liquid |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106420809A CN106420809A (en) | 2017-02-22 |
CN106420809B true CN106420809B (en) | 2017-08-08 |
Family
ID=58163763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610787864.1A Active CN106420809B (en) | 2016-08-31 | 2016-08-31 | A kind of ophthalmologic operation perfusion liquid |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106420809B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024044342A1 (en) * | 2022-08-26 | 2024-02-29 | Marizyme, Inc. | Antioxidant-containing eye drop formulations and methods of prevention and/or treatment using same |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108671270A (en) * | 2018-05-25 | 2018-10-19 | 爱博诺德(北京)医疗科技有限公司 | Viscoelastic agent material with redox characteristic |
CN109771370B (en) * | 2019-02-28 | 2021-03-30 | 厦门大学 | Anterior chamber perfusate for intraocular surgery and application thereof |
CN111001010B (en) * | 2019-12-28 | 2022-09-02 | 潍坊医学院附属医院 | External eye operation flushing fluid and preparation method thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101062051A (en) * | 2007-05-25 | 2007-10-31 | 北京大学人民医院 | Injection liquid for vitreous cutting operation and the preparing method thereof |
CN101125149B (en) * | 2007-09-19 | 2010-09-29 | 温州医学院眼视光研究院 | Ophthalmic operating special-purpose colored perfusate |
EP2780022B2 (en) * | 2011-11-14 | 2022-09-07 | Astellas Institute for Regenerative Medicine | Pharmaceutical preparations of human rpe cells and uses thereof |
-
2016
- 2016-08-31 CN CN201610787864.1A patent/CN106420809B/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024044342A1 (en) * | 2022-08-26 | 2024-02-29 | Marizyme, Inc. | Antioxidant-containing eye drop formulations and methods of prevention and/or treatment using same |
Also Published As
Publication number | Publication date |
---|---|
CN106420809A (en) | 2017-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106420809B (en) | A kind of ophthalmologic operation perfusion liquid | |
CN102631558A (en) | Medicament for treating eye disease and preparation method of medicament | |
CN100522162C (en) | New pranoprofen eye drops and its preparation method | |
CN101416741A (en) | Health-care food for relieving visual fatigue | |
CN201029958Y (en) | Non-penetrating integrated artificial cornea | |
RU2465872C1 (en) | Method of prevention and treatment of excessive scarring after anti-glaucoma operation | |
CN105617350A (en) | Extraction method of sheep sclera collagen, ophthalmic gel and preparation method thereof | |
Hill | Corneal vascularization after cataract extraction by zonulysis | |
CN102512467A (en) | Ophthalmic preparation of panax notoginseng saponins and preparation method thereof | |
CN105832977A (en) | Eye-protecting nourishing solution and preparation method thereof | |
Barraquer | Enzymatic zonulolysis in lens extraction | |
CN104814977B (en) | A kind of ophthalmic flexibility hydrosol assistant agent | |
CN104886574B (en) | A kind of middle-aged and old health food for improving the health care of sleep protection eyesight and preparation method thereof | |
Fankhauser et al. | Neodymium Q-switched YAG laser lysis of iris lens synechiae | |
Cavallini et al. | Bimanual microphacoemulsification and Acri. Smart intraocular lens implantation combined with vitreoretinal surgery | |
CN101804057A (en) | Chuagxiongzine ophthalmic preparation | |
CN111956737A (en) | Traditional Chinese medicine for nourishing eyes, preparation method and Chinese-style eye nourishing equipment | |
RU2303457C1 (en) | Method for applying enzymotherapy | |
CN1079235C (en) | Acetazolamide microemulsion as eyedrops for treating glaucoma and its preparing process | |
RU2345740C1 (en) | Method of dystrophic eye diseases treatment by means of medicinal mud remedy "relict-05" | |
CN100387260C (en) | Eye medicine for treating senile cataract and its pH value regulating method and preparing process | |
Huang et al. | Expression of inflammatory factors in aqueous humor of contralateral eyes after phacoemulsification in diabetes mellitus with cataract | |
CN106074626A (en) | A kind of alleviate dry and astringent antibacterial liquid of eye and preparation method thereof | |
SU1398859A1 (en) | Method of extracapsular extraction of immature cataract | |
CN116115708A (en) | Eye drop for treating myopia, astigmatism and presbyopia and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: 318020 No. 888 north courtyard Road, Huangyan District, Taizhou, Zhejiang Patentee after: Jinmin health management Limited by Share Ltd Address before: 318020 No. 888 north courtyard Road, Huangyan District, Taizhou, Zhejiang Patentee before: Zhejiang Chiming Pharmaceutical Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |